Linda E Kelemen
Overview
Explore the profile of Linda E Kelemen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
4638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin L, OConnor J, Rubaiya F, Kelemen L
J Am Med Dir Assoc
. 2024 Dec;
26(2):105395.
PMID: 39653326
Objectives: To investigate pre- and post-pandemic demographic profiles of attendees at adult day care (ADC) facilities in the US South, and survey providers for their experience during the pandemic. Design:...
2.
Nelson B, Hamilton P, Phung M, Milne K, Harris B, Thornton S, et al.
J Clin Invest
. 2024 Oct;
134(24).
PMID: 39470729
BACKGROUNDDespite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive 10 or more years after standard treatment.METHODSWe evaluated the tumor microenvironment of this...
3.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3481-3498.
PMID: 38837893
Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences...
4.
Dareng E, Coetzee S, Tyrer J, Peng P, Rosenow W, Chen S, et al.
Am J Hum Genet
. 2024 May;
111(6):1061-1083.
PMID: 38723632
To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981...
5.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
medRxiv
. 2023 Nov;
PMID: 37986741
Background: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian high-grade serous carcinoma (HGSC), which frequently co-occurs with alterations in homologous recombination DNA repair genes including...
6.
Kobel M, Kang E, Weir A, Rambau P, Lee C, Nelson G, et al.
J Pathol Clin Res
. 2023 Mar;
9(3):208-222.
PMID: 36948887
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC],...
7.
Weir A, Kang E, Meagher N, Nelson G, Ghatage P, Lee C, et al.
Br J Cancer
. 2022 Nov;
128(1):137-147.
PMID: 36323878
Background: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied...
8.
Meagher N, Gorringe K, Wakefield M, Bolithon A, Pang C, Chiu D, et al.
Clin Cancer Res
. 2022 Oct;
28(24):5383-5395.
PMID: 36222710
Purpose: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating primary MOC from gastrointestinal (GI) metastases to the...
9.
Dareng E, Tyrer J, Barnes D, Jones M, Yang X, Aben K, et al.
Eur J Hum Genet
. 2022 Mar;
30(5):630-631.
PMID: 35314806
No abstract available.
10.
Dareng E, Tyrer J, Barnes D, Jones M, Yang X, Aben K, et al.
Eur J Hum Genet
. 2022 Jan;
30(3):349-362.
PMID: 35027648
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance...